ARQT
Price
$34.05
Change
+$2.05 (+6.41%)
Updated
Nov 4 closing price
Capitalization
4.28B
Earnings call today
Intraday BUY SELL Signals
XNCR
Price
$35.03
Change
+$4.39 (+14.33%)
Updated
Nov 4 closing price
Capitalization
2.6B
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs XNCR

ARQT vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARQT vs. XNCR commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and XNCR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARQT with price predictions
Nov 03, 2026

Aroon Indicator for ARQT shows an upward move is likely

ARQT's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.

ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for ARQT moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 58 of 69 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ARQT broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.403) is normal, around the industry mean (3.051). ARQT's P/E Ratio (154.773) is considerably higher than the industry average of (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (439.647).

A.I.Advisor
a Summary for XNCR with price predictions
Nov 03, 2026

XNCR in upward trend: 10-day moving average moved above 50-day moving average on October 28, 2026

The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 52 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.

The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +19.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

XNCR broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.176) is normal, around the industry mean (3.051). P/E Ratio (-16.218) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARQT vs XNCR: Fundamental Ratings
ARQT
XNCR
OUTLOOK RATING
1..100
4138
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
5497
PRICE GROWTH RATING
1..100
3734
P/E GROWTH RATING
1..100
2694
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (18) in the Biotechnology industry is significantly better than the same rating for ARQT (99) in the null industry. This means that XNCR’s stock grew significantly faster than ARQT’s over the last 12 months.

ARQT's Profit vs Risk Rating (76) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ARQT’s stock grew similarly to XNCR’s over the last 12 months.

ARQT's SMR Rating (54) in the null industry is somewhat better than the same rating for XNCR (97) in the Biotechnology industry. This means that ARQT’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's Price Growth Rating (34) in the Biotechnology industry is in the same range as ARQT (37) in the null industry. This means that XNCR’s stock grew similarly to ARQT’s over the last 12 months.

ARQT's P/E Growth Rating (26) in the null industry is significantly better than the same rating for XNCR (94) in the Biotechnology industry. This means that ARQT’s stock grew significantly faster than XNCR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTXNCR
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 9 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 22 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (ARQT: $32.00 vs. XNCR: $30.64)
Brand notoriety: ARQT and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 64% vs. XNCR: 75%
Market capitalization -- ARQT: $4.28B vs. XNCR: $2.6B
ARQT [@Biotechnology] is valued at $4.28B. XNCR’s [@Biotechnology] market capitalization is $2.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, ARQT is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • ARQT’s TA Score: 5 bullish, 5 bearish.
  • XNCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ARQT and XNCR are a good buy in the short-term.

Price Growth

ARQT (@Biotechnology) experienced а +1.01% price change this week, while XNCR (@Biotechnology) price change was +2.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.

Reported Earning Dates

ARQT is expected to report earnings on Nov 04, 2026.

XNCR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-3.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+2.37%
XNCR - ARQT
48%
Loosely correlated
+3.30%
PTGX - ARQT
46%
Loosely correlated
+0.62%
PTCT - ARQT
44%
Loosely correlated
+11.89%
TRDA - ARQT
42%
Loosely correlated
-7.63%
TGTX - ARQT
42%
Loosely correlated
+1.33%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPFP49.320.12
+0.25%
JPMorgan Managed Futures Plus ETF (JPFP)
TXUG25.980.06
+0.23%
Thornburg International Growth Fund ETF (TXUG)
BYLD21.75-0.09
-0.41%
iShares Yield Optimized Bond ETF (BYLD)
IBHL24.31-0.10
-0.42%
iShares iBonds 2032 Term High Yield and Income ETF (IBHL)
FENY36.59-0.30
-0.81%
Fidelity MSCI Energy Index ETF (FENY)